SCHEMBL4190722

SCHEMBL4190722

C[C@@H](CC1CCCC1)NCc1ccccc1NS(=O)(=O)c1ccc(NS(=O)(=O)c2nccn2C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.42
PKM P14618 1/20 0.42
ALDH1A1 P00352 6/20 0.38
MAPT P10636 5/20 0.38
LMNA P02545 4/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
USP1 O94782 1/20 0.38
POLB P06746 2/20 0.36
HTT P42858 1/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
MCL1 Q07820 1/20 0.34
TRPM8 Q7Z2W7 1/20 0.34
USP30 Q70CQ3 1/20 0.34
CTSL P07711 1/20 0.34
CTSS P25774 1/20 0.34
CTSK P43235 1/20 0.34
KCNA5 P22460 1/20 0.34
PLK1 P53350 1/20 0.33
PLK3 Q9H4B4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4194408 0.93 KDM4E (0.39) KDM4EPKMALDH1A1MAPTLMNA
SCHEMBL4194953 0.83 KDM4E (0.46) KDM4EPKMALDH1A1MAPTLMNA
SCHEMBL4190913 0.83 KDM4E (0.50) KDM4EPKMALDH1A1MAPTLMNA
SCHEMBL4191293 0.83 KDM4E (0.50) KDM4EPKMALDH1A1MAPTLMNA
SCHEMBL4193042 0.83 KDM4E (0.45) KDM4EPKMALDH1A1MAPTLMNA
SCHEMBL4190400 0.82 KDM4E (0.52) KDM4EPKMALDH1A1MAPTLMNA
SCHEMBL4200042 0.82 KDM4E (0.46) KDM4EPKMALDH1A1MAPTLMNA
SCHEMBL4188316 0.81 KDM4E (0.51) KDM4EPKMALDH1A1MAPTLMNA
SCHEMBL4193484 0.81 KDM4E (0.47) KDM4EPKMALDH1A1MAPTLMNA
SCHEMBL4194027 0.81 PKM (0.52) KDM4EPKMALDH1A1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 KDM4E 3328/4885PKM 1855/4885ALDH1A1 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.